AstraZeneca UK Ltd / Cambridge Antibody Technology plc

OFT closed case: Anticipated acquisition by AstraZeneca UK Limited of Cambridge Antibody Technology plc

Affected market: Biopharmaceuticals

No. ME/2433/06

On the basis of the information available to it, the OFT has decided that the anticipated acquisition by AstraZeneca UK Limited of Cambridge Antibody Technology plc does not qualify for investigation under the mergers provisions of the Enterprise Act 2002 (the Act), because neither the UK turnover test nor the share of supply test in section 23 of the Act is met. A relevant merger situation has, therefore, not been created.

Published 30 May 2006